|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis CE, Lin CC, Mariotto AB, et al:
Cancer treatment and survivorship statistics, 2014. CA Cancer J
Clin. 64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khalighinejad N, Hariri H, Behnamfar O,
Yousefi A and Momeni A: Adenoviral gene therapy in gastric cancer:
A review. World J Gastroenterol. 14:180–184. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leja M, Wex T and Malfertheiner P: Markers
for gastric cancer premalignant lesions: Where do we go? Dig Dis.
30:268–276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Amedei A, Della Bella C, Silvestri E,
Prisco D and D'Elios MM: T cells in gastric cancer: Friends or
foes. Clin Dev Immunol. 2012:6905712012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Toiyama Y, Okugawa Y and Goel A: Dna
methylation and microRNA biomarkers for noninvasive detection of
gastric and colorectal cancer. Biochem Biophys Res Commun.
455:43–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Felipe AV, Oliveira J, Chang PY, et al:
RNA interference: a promising therapy for gastric cancer. Asian Pac
J Cancer Prev. 15:5509–5515. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pasquinelli AE: MicroRNAs and their
targets: Recognition, regulation and an emerging reciprocal
relationship. Nat Rev Genet. 13:271–282. 2012.PubMed/NCBI
|
|
9
|
Wang Y and Lee CG: MicroRNA and
cancer-focus on apoptosis. J Cell Mol Med. 13:12–23. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bueno MJ, Pérez de Castro I and Malumbres
M: Control of cell proliferation pathways by microRNAs. Cell Cycle.
7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liang LH and He XH: Macro-management of
microRNAs in cell cycle progression of tumor cells and its
implications in anti-cancer therapy. Acta Pharmacol Sin.
32:1311–1320. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lowery AJ, Miller N, McNeill RE and Kerin
MJ: MicroRNAs as prognostic indicators and therapeutic targets:
Potential effect on breast cancer management. Clin Cancer Res.
14:360–365. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nouraee N and Calin GA: MicroRNAs as
cancer biomarkers. Microrna. 2:102–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berindan-Neagoe I, Monroig Pdel C,
Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer
diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Maroof H, Salajegheh A, Smith RA and Lam
AK: Role of microRNA-34 family in cancer with particular reference
to cancer angiogenesis. Exp Mol Pathol. 97:298–304. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balca-Silva J, Sousa Neves S, Goncalves
AC, et al: Effect of miR-34b overexpression on the radiosensitivity
of non-small cell lung cancer cell lines. Anticancer Res.
32:1603–1609. 2012.PubMed/NCBI
|
|
17
|
Li Y, Guessous F, Zhang Y, et al:
MicroRNA-34a inhibits glioblastoma growth by targeting multiple
oncogenes. Cancer Res. 69:7569–7576. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao W, Fan R, Wang L, et al: Expression
and regulatory function of miRNA-34a in targeting survivin in
gastric cancer cells. Tumour Biol. 34:963–971. 2013. View Article : Google Scholar
|
|
19
|
Dang Y, Luo D, Rong M and Chen G:
Underexpression of miR-34a in hepatocellular carcinoma and its
contribution towards enhancement of proliferating inhibitory
effects of agents targeting c-MET. PLoS One. 8:e610542013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pineau P, Volinia S, McJunkin K, et al:
miR-221 overexpression contributes to liver tumorigenesis. Proc
Natl Acad Sci USA. 107:264–269. 2010. View Article : Google Scholar :
|
|
21
|
Yao Y, Suo AL, Li ZF, et al: MicroRNA
profiling of human gastric cancer. Mol Med Rep. 2:963–970.
2009.PubMed/NCBI
|
|
22
|
Braun CJ, Zhang X, Savelyeva I, Wolff S,
Moll UM, Schepeler T, Ørntoft TF, Andersen CL and Dobbelstein M:
p53-Responsive micrornas 192 and 215 are capable of inducing cell
cycle arrest. Cancer Res. 68:10094–10104. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cerami E, Gao J, Dogrusoz U, et al: The
cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao J, Aksoy BA, Dogrusoz U, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBio-Portal. Sci Signal. 6:pl12013. View Article : Google Scholar
|
|
25
|
Camp RL, Dolled-Filhart M and Rimm DL:
X-tile: a new bio-informatics tool for biomarker assessment and
outcome-based cut-point optimization. Clin Cancer Res.
10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Krek A, Grün D, Poy MN, et al:
Combinatorial microRNA target predictions. Nat Genet. 37:495–500.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Huang J, Yang N, et al: microRNAs
exhibit high frequency genomic alterations in human cancer. Proc
Natl Acad Sci USA. 13:9136–9141. 2006. View Article : Google Scholar
|
|
28
|
Hsu SD, Lin FM, Wu WY, et al: miRTarBase:
A database curates experimentally validated microRNA-target
interactions. Nucleic Acids Res. 39:D163–D169. 2011. View Article : Google Scholar
|
|
29
|
Calin GA, Ferracin M, Cimmino A, et al: A
MicroRNA signature associated with prognosis and progression in
chronic lymphocytic leukemia. N Engl J Med. 353:1793–1801. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Parrella P, Barbano R, Pasculli B, et al:
Evaluation of microRNA-10b prognostic significance in a prospective
cohort of breast cancer patients. Mol Cancer. 13:1422014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hermansen SK, Dahlrot RH, Nielsen BS,
Hansen S and Kristensen BW: MiR-21 expression in the tumor cell
compartment holds unfavorable prognostic value in gliomas. J
Neurooncol. 111:71–81. 2013. View Article : Google Scholar
|
|
32
|
Tu Y, Gao X, Li G, et al: MicroRNA-218
inhibits glioma invasion, migration, proliferation and cancer
stem-like cell self-renewal by targeting the polycomb group gene
Bmi1. Cancer Res. 73:6046–6055. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aqeilan RI, Calin GA and Croce CM: miR-15a
and miR-16-1 in cancer: Discovery, function and future
perspectives. Cell Death Differ. 17:215–220. 2010. View Article : Google Scholar
|
|
34
|
Bonci D, Coppola V, Musumeci M, et al: The
miR-15a-miR-16-1 cluster controls prostate cancer by targeting
multiple oncogenic activities. Nat Med. 14:1271–1277. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Houbaviy HB, Murray MF and Sharp PA:
Embryonic stem cell-specific MicroRNAs. Dev Cell. 5:351–358. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dostie J, Mourelatos Z, Yang M, Sharma A
and Dreyfuss G: Numerous microRNPs in neuronal cells containing
novel microRNAs. RNA. 9:180–186. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lim LP, Glasner ME, Yekta S, Burge CB and
Bartel DP: Vertebrate microRNA genes. Science. 299:15402003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He L, He X, Lim LP, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cho WC: OncomiRs: The discovery and
progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lutterbach B, Zeng Q, Davis LJ, et al:
Lung cancer cell lines harboring MET gene amplification are
dependent on Met for growth and survival. Cancer Res. 67:2081–2088.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplifi-cation leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Takeuchi H, Bilchik A, Saha S, et al:
c-MET expression level in primary colon cancer: A predictor of
tumor invasion and lymph node metastases. Clin Cancer Res.
9:1480–1488. 2003.PubMed/NCBI
|
|
43
|
Sawada K, Radjabi AR, Shinomiya N, et al:
c-Met overexpression is a prognostic factor in ovarian cancer and
an effective target for inhibition of peritoneal dissemination and
invasion. Cancer Res. 67:1670–1679. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kammula US, Kuntz EJ, Francone TD, et al:
Molecular co-expression of the c-Met oncogene and hepatocyte growth
factor in primary colon cancer predicts tumor stage and clinical
outcome. Cancer Lett. 248:219–228. 2007. View Article : Google Scholar
|
